Study Evaluating Safety, Tolerability and Efficacy of YM150 in Subjects With Acute Coronary Syndromes (RUBY-1)
A Randomized, Double-Blind, Placebo Controlled Multi-Center and Parallel Group Study of the Safety, Tolerability and Efficacy of YM150 in Combination With Standard Treatment in Secondary Prevention of Ischemic Vascular Events in Subjects With Acute Coronary Syndromes
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Ciudad Autonoma de Buenos Aires, Argentina, C1280AEB
-
Corrientes, Argentina, W3400AMZ
-
Salta, Argentina, A4406CLA
-
Salta, Argentina, A4400AWG
-
-
-
-
-
Concord, Australia, 2139
-
Douglas, Australia, 4814
-
-
-
-
-
Aalst, Belgium, B9300
-
Bonheiden, Belgium, B2820
-
Brussels, Belgium, 1200
-
Brussels, Belgium, B1000
-
Brussels, Belgium, B1070
-
Genk, Belgium, B3600
-
Leper, Belgium, 8900
-
Ottignies, Belgium, 1340
-
-
-
-
-
Brasilia, Brazil, 70658-700
-
Porto Alegre, Brazil, 90610-000
-
Recife, Brazil, 52051-380
-
Salvador, Brazil, 41810-010
-
Sao Jose, Brazil, 88103-901
-
Sao Paulo, Brazil, 04012-180
-
Uberlandia, Brazil, 38400-368
-
-
-
-
-
Cambridge, Canada, N1R 6V6
-
Hamilton, Canada, L8L 2X2
-
Laval, Canada, H7M 3L9
-
Longueuil, Canada, J4M 2A5
-
Montreal, Canada, G1V 4G5
-
Montreal, Canada, H3G 1A4
-
Montreal, Canada, J6V 2H2
-
St Jerome, Canada, J7Z 5T3
-
-
-
-
-
Barranquilla, Colombia
-
Bogota, Colombia
-
Cartagena, Colombia
-
Floridablanca, Colombia
-
-
-
-
-
Beroun, Czech Republic, 266 01
-
Brno, Czech Republic, 625 00
-
Brno, Czech Republic, 636 00
-
Jihlava, Czech Republic, 586 33
-
Kladno, Czech Republic, 272 59
-
Liberec, Czech Republic, 460 63
-
Pardubice, Czech Republic, 532 03
-
Prague, Czech Republic, 10034
-
Sternberk, Czech Republic, 785 01
-
Vsetin, Czech Republic, 755 01
-
Zlin, Czech Republic, 762 75
-
-
-
-
-
Copenhagen, Denmark, 2100
-
-
-
-
-
Paris Cedex 18, France, 75877
-
-
-
-
-
Bad Nauheim, Germany, 61231
-
Dresden, Germany, 101067
-
Freiburg, Germany
-
Kassel, Germany, 34121
-
Neuss, Germany, 41464
-
-
-
-
-
Balatonfured, Hungary, 8230
-
Budapest, Hungary, 1122
-
Budapest, Hungary, 1096
-
Debrecen, Hungary, 4032
-
Miskolc, Hungary, 3526
-
Nyiregyhaza, Hungary, 4400
-
Szeged, Hungary, 6720
-
Szekesfehervar, Hungary, 8000
-
Zalaegerszeg, Hungary, 8900
-
-
-
-
-
Ahmedabad, India, 380015
-
Ahmedabad, India, 380014
-
Ahmedabad, India, 380 006
-
Hyderabaad, India, 500001
-
Hyderabaad, India, 500072
-
Mangalore, India, 575004
-
Nagpur, India, 440012
-
New Delhi, India, 110018
-
Tamil Nadu, India, 600037
-
Tirupati, India, 517507
-
-
-
-
-
Busan, Korea, Republic of, 603-714
-
Gwangju, Korea, Republic of, 501-757
-
Gyeonggi-do, Korea, Republic of, 471-020
-
Inchon, Korea, Republic of, 405-760
-
Seoul, Korea, Republic of, 158-710
-
Seoul, Korea, Republic of, 135-720
-
-
-
-
-
Colonia Burocratas del Estado, Mexico, 78200
-
Guadalajara, Mexico, 44340
-
Guadalajara, Mexico, 44290
-
Merida, Mexico, 97129
-
Morelia, Mexico, CP 58070
-
Zapopan, Mexico, 45040
-
-
-
-
-
Amsterdam, Netherlands, 1061 AE
-
Heerlen, Netherlands, 6419 PC
-
Helmond, Netherlands, 5707 HA
-
Hertogenbosch, Netherlands, 5211 NL
-
Leeuwarden, Netherlands, 8934 AD
-
Nijmegen, Netherlands, 6532 SZ
-
Oss, Netherlands, 5342 BT
-
-
-
-
-
Bialystok, Poland, 15-276
-
Elblag, Poland, 82-300
-
Gdansk, Poland, 80-952
-
Inowroclaw, Poland, 88-100
-
Krakow, Poland, 31-202
-
Przemysl, Poland, 37-700
-
-
-
-
-
Baia Mare, Romania, 430110
-
Braila, Romania, 810249
-
Bucuresti, Romania, 014461
-
Bucuresti, Romania, 020152
-
Craiova, Romania, 200642
-
Oradea, Romania, 410169
-
Targoviste, Romania, 130083
-
Targu Mures, Romania, 540136
-
-
-
-
-
Chelyabinsk, Russian Federation, 454136
-
Kemerovo, Russian Federation, 650002
-
Moscow, Russian Federation, 111539
-
Moscow, Russian Federation, 119620
-
Moscow, Russian Federation, 115093
-
Moscow, Russian Federation, 127644
-
Saratov, Russian Federation, 410054
-
Tomsk, Russian Federation, 643012
-
Tyumen, Russian Federation, 625023
-
Tyumen, Russian Federation, 625026
-
Yaroslavl, Russian Federation, 150062
-
-
-
-
-
Martin, Slovakia, 036 59
-
Nitra, Slovakia, 949 01
-
Rimavska Sobota, Slovakia, 979 01
-
Ruzomberok, Slovakia, 034 26
-
-
-
-
-
George, South Africa, 6529
-
Johannesburg, South Africa, 2193
-
Kuilsriver, South Africa, 7580
-
Parow, South Africa, 7500
-
Pinelands, South Africa, 7405
-
Tongaat, South Africa, 4399
-
Umhlanga, South Africa, 4319
-
Western Cape, South Africa, 7130
-
Worcester, South Africa, 6850
-
-
-
-
-
Kharkiv, Ukraine, 61002
-
Kharkiv, Ukraine, 61178
-
Kyiv, Ukraine, 03152
-
Zaporizhzhya, Ukraine, 69000
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- has a diagnosis of STE-ACS, NSTE-ACS as index event according to accepted guidelines such as the ESC or AHA guidelines
- has elevated cardiac biomarkers
Exclusion Criteria:
- is planned for myocardial revascularization (e.g., Coronary Artery Bypass Graft (CABG) or elective or staged PCI) or any other invasive procedure with increased risk for bleeding (i.e. elective surgical procedures) within 60 days after randomization
- has had recent stroke or TIA ≤ 12 months prior to index event
- has persistent BP of 160 mmHg systolic or higher and/or 100 mmHg diastolic or higher at baseline with or without medication
- has participated in another clinical trial of an investigational drug (including placebo) or device within 30 days (or the limit set by national law, whichever is longer) of signing informed consent for the present study
- has participated in any YM150 clinical trials
- requires ongoing parenteral or oral anticoagulant therapy
- has active bleeding or is in the opinion of the investigator at high risk of bleeding during the study
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: 1. YM150 Dose V, twice daily
|
oral
|
|
Experimental: 2. YM150 Dose W, once daily
|
oral
|
|
Experimental: 3. YM150 Dose X, twice daily
|
oral
|
|
Experimental: 4. YM150 Dose Y, once daily
|
oral
|
|
Experimental: 5. YM150 Dose Y, twice daily
|
oral
|
|
Experimental: 6. YM150 Dose Z, once daily
|
oral
|
|
Placebo Comparator: 7. Placebo
|
oral
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of Major and Clinically Relevant Non Major bleeding events according to International Society of Thrombosis and Hemostasis (ISTH) definition
Time Frame: 6 Months
|
6 Months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Incidence of Major and Clinically Relevant Non Major bleeding events
Time Frame: 30 Days
|
30 Days
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Myocardial Ischemia
- Heart Diseases
- Cardiovascular Diseases
- Vascular Diseases
- Disease
- Syndrome
- Acute Coronary Syndrome
- Molecular Mechanisms of Pharmacological Action
- Enzyme Inhibitors
- Protease Inhibitors
- Factor Xa Inhibitors
- Antithrombins
- Serine Proteinase Inhibitors
- Anticoagulants
- Darexaban
Other Study ID Numbers
Other Study ID Numbers
- 150-CL-201
- 2008-005972-29 (EudraCT Number)
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.